Seres Therapeutics Inc (MCRB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.54. The fair price of Seres Therapeutics Inc (MCRB) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 8.31 USD , Seres Therapeutics Inc By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：8.31

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Seres Therapeutics Inc (MCRB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Seres Therapeutics Inc (MCRB) has a current Price-to-Book (P/B) ratio of 3.04. Compared to its 3-year average P/B ratio of 2.69, the current P/B ratio is approximately 12.87% higher. Relative to its 5-year average P/B ratio of 7.49, the current P/B ratio is about -59.45% higher. Seres Therapeutics Inc (MCRB) has a Forward Free Cash Flow (FCF) yield of approximately -17.05%. Compared to its 3-year average FCF yield of -75.02%, the current FCF yield is approximately -77.27% lower. Relative to its 5-year average FCF yield of -48.53%, the current FCF yield is about -64.87% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MCRB competitors is 1.00, providing a benchmark for relative valuation. Seres Therapeutics Inc Corp (MCRB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MCRB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MCRB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MCRB currently overvalued or undervalued?

What is Seres Therapeutics Inc (MCRB) fair value?

MCRB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Seres Therapeutics Inc (MCRB) is between +Inf to +Inf according to relative valuation method.

How does MCRB's valuation metrics compare to the industry average?

The average P/S ratio for MCRB's competitors is 1.00, providing a benchmark for relative valuation. Seres Therapeutics Inc Corp (MCRB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Seres Therapeutics Inc (MCRB) as of Mar 02 2026?

As of Mar 02 2026, Seres Therapeutics Inc (MCRB) has a P/B ratio of 3.04. This indicates that the market values MCRB at 3.04 times its book value.

What is the current FCF Yield for Seres Therapeutics Inc (MCRB) as of Mar 02 2026?

As of Mar 02 2026, Seres Therapeutics Inc (MCRB) has a FCF Yield of -17.05%. This means that for every dollar of Seres Therapeutics Inc's market capitalization, the company generates -17.05 cents in free cash flow.

What is the current Forward P/E ratio for Seres Therapeutics Inc (MCRB) as of Mar 02 2026?

As of Mar 02 2026, Seres Therapeutics Inc (MCRB) has a Forward P/E ratio of -1.97. This means the market is willing to pay $-1.97 for every dollar of Seres Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Seres Therapeutics Inc (MCRB) as of Mar 02 2026?

As of Mar 02 2026, Seres Therapeutics Inc (MCRB) has a Forward P/S ratio of 0.00. This means the market is valuing MCRB at $0.00 for every dollar of expected revenue over the next 12 months.

MCRB Valuation